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Human immunodeficiency virus (HIV) constitutes an un- 
precedented challenge to medical science. Once an HIV 
infection is established, its clinical course, while pro- 
tracted, is generally inexorable. With the possible excep- 
tion of a group of recently described "long-term nonpro- 
gressors," virtually all HIV-infected individuals eventually 
develop acquired immunodeficiency syndrome (AIDS), 
the outcome of which is almost invariably fatal. 
The course of HIV infection is quite different from that 
encountered in the great majority of infectious diseases. 
The more normal experience in the contest between 
pathogens and their hosts is that of an acute infection in 
which some fraction of those infected recover and, thereaf- 
ter, express solid immunity, protecting them against the 
same or related agents. Generally, the nature of protective 
immunity expressed by those that have recovered from 
infection may be used as a guide to the type of response 
that a vaccine should induce to provide protection. In the 
case of HIV, it has generally been believed that infected 
individuals never purge themselves of the virus, although 
this now appears to have been an oversimplification. The 
lack of information that would usually be provided by study 
of those who had recovered has meant that no correlation 
between type of immunity and protection could be drawn 
to guide scientists in their efforts to develop protective 
anti-HIV vaccines. 
A Vigorous Immune Response Occurs in Response 
to HIV Infection 
Does an effective immune response occur in infected indi- 
viduals? Perhaps surprisingly, in view of the apparent inev- 
itability of progression, the weight of evidence strongly 
suggests that a highly effective immune response does 
occur and that it contains the virus for a long period of 
time, although it rarely eradicates it. Infected individuals 
produce large amounts of anti-HIV antibody, the appear- 
ance of which has become the hallmark for the diagnosis 
of infection. Neutralizing antibody is commonly observed, 
although it is generally not detectable until after the initially 
high viral titers have fallen to the low levels that character- 
ize the period of clinical latency (Robert et al., 1988; Saw- 
yer et al., 1990). Indeed, development of neutralizing anti- 
body that is cross-reactive on HIV strains other than that 
causing the infection may be even more protracted. The 
role of such neutralizing antibody in the control of HIV in 
the infected individual is not truly understood. Indeed, we 
do not yet know whether the small subset of infected indi- 
viduals who become long-term nonprogressors may show 
earlier and more vigorous production of neutralizing anti- 
bodies than do the great majority of individuals in whom 
infection is progressive. 
In contrast with the pace of appearance of neutralizing 
antibody, cytotoxic T cells (CTLs) specific for epitopes in 
the envelope glycoprotein, the gag-derived proteins, and 
other HIV proteins (including the reverse transcriptase) 
can be detected quite early in infection (Walker et al., 
1989). Based mainly on the correlation of the time at which 
the initial viremia diminishes and at which CTLs can be 
detected, it is widely held that these cells, by killing virally 
infected cells prior to their production of additional infec- 
tious virus, are responsible for the striking diminution in 
viral burden (Walker, 1990). 
Does the Immune Response Ever Eliminate 
or Fully Control Infection? 
The recognition that a vigorous immune response accom- 
panies infection raises the issue of whether this response 
ever actually controls HIV. This has become a much more 
active subject of research with the appreciation that a set 
of HIV-infected individuals can survive for prolonged peri- 
ods of time with essentially normal numbers of CD4 + T 
cells (Cao et al., 1995; Pantaleo et al., 1995; Kirchhoff et 
al., 1995). It is quite likely that no single factor explains 
the control of infection in all long-term nonprogressors. 
Indeed, as I will discuss subsequently, some of these indi- 
viduals may have been infected with a virus of limited repli- 
cation competence, pathogenicity, or both (Kirchhoff et 
al., 1995). However, many long-term nonprogressors ap- 
pear to have been infected with pathogenic viruses that 
they have controlled (Huang et al., 1995). Indeed, in many 
of these individuals, viral burden is very low (Cao et al., 
1995). 
No definitive information yet exists to explain this control 
of HIV, but in many cases, long-term nonprogressors pos- 
sess CD8 + T cells that strikingly limit the capacity of HIV 
from their CD4 ÷ T cells to infect peripheral blood mononu- 
clear cells (PBMCs) that have been activated with phyto- 
hemagglutinin (PHA). Pure CD4 ÷ T cells from long-term 
nonprogressors are quite effective in transmitting HIV to 
PHA-activated PBMCs, but addition of their CD8 + T cells 
strikingly suppresses such infection. Levy and his col- 
leagues (Mackewicz et al., 1994) have shown that super- 
natants of CD8 ÷ T cells can inhibit in vitro infection. They 
have argued that this CD8 cell-derived soluble factor, 
which appears to be distinct from any known cytokine, 
may act to limit infectability in vivo as well as in vitro. 
Whether this factor explains the lack of progression seen 
in long-term nonprogressors is unknown. Obviously, char- 
acterization of this factor is a priority goal. 
The possibility that an HIV that had established an infec- 
tion may then be eliminated has been raised by results 
from the study of a child from whom HIV was isolated 
neonatally but who was seronegative and had no recover- 
able virus nor any clinical symptoms at the age of 5 (Bryson 
et al., 1995). This infant had positive viral cultures on two 
separate occasions in the first year of life, implying that 
he had acquired HIV from his mother during pregnancy 
or delivery. Thus far, we know little about the nature of 
Cell 
178 
the anti-HIV immune response made by this child nor do 
we know whether the infecting virus was fully virulent. The 
results of studies to answer these questions, to the extent 
that they are feasible, will be eagerly awaited. 
An example consistent with immune elimination of HIV 
has been reported by Shearer and his colleagues (Pinto 
et al., 1995). They studied a set of health care workers 
who had been exposed to HIV-contaminated blood and 
compared them with a similar number of individuals ex- 
posed to blood from uninfected individuals. None of those 
exposed to HIV + blood seroconverted, but this is not sur- 
prising since the likelihood of developing an established 
HIV infection from such an exposure is quite low. However, 
of 20 persons exposed to HIV-infected blood, 7 developed 
CTLs specific for HIV peptides in association with class I 
major histocompatibility complex (MHC) molecules. None 
of those exposed to uninfected blood had such CTLs. 
The development of class I MHC-restricted, HIV-specific 
CTLs suggests that an actual HIV infection occurred. This 
conclusion is based on the cell biology of antigen presenta- 
tion by class I MHC molecules (Germain and Margulies, 
1993). Class I-restricted antigen presentation generally 
requires endogenous production of the protein from which 
the peptide is derived. Such production of viral protein 
implies viral infection of the cells that evoked the HIV- 
specific CTLs. Since no evidence of infection could be 
detected in the exposed health care workers and CTLs 
were no longer discerned a year after exposure, it would 
appear that the period of putative HIV infection was tran- 
sient. The relationship of the CTLs to the presumed purg- 
ing of HIV is not established, although it would be quite 
plausible that the CTLs did eliminate the virus. 
Shearer has argued that the reason these individuals 
were protected against he development of an established 
HIV infection is not only that small amounts of virus may 
present a challenge with which the immune system can 
cope but also because low doses of antigen may preferen- 
tially elicit a response dominated by the production of inter- 
feron~ (IFN~,) and of CTLs (Bretscher et al., 1992). Indeed, 
Clerici et al. (1994) have reported that infection with very 
limited amounts of fully virulent simian immunodeficiency 
virus (SIV) can protect macaques against a subsequent 
challenge with a normally infectious dose of SIV. 
An Established Infection with an Attenuated Virus 
May Induce Robust Immunity 
The inference that protective immune responses occur 
quite commonly may be drawn from studies indicating the 
difficulty in superinfecting primates. Infections with attenu- 
ated viruses appear to result in a state of solid immunity 
protecting against subsequent infection with fully virulent 
virus. The most striking example of such protection is the 
robust resistance of macaques that have been infected 
with attenuated SIVs, such as those that are defective in 
the nef gene. Desrosiers and his colleagues (Daniel et 
al., 1992) have shown that these animals contain DNA 
sequences of the defective virus, although their viral bur- 
dens are very low. Despite the continued presence of the 
attenuated SIV, the macaques display striking resistance 
to infection with large amounts of fully virulent SIV. In other 
experiments, protection was observed not only against 
free SIV but also against SIV-infected cells (Almond et al., 
1995). The time required for induction of this resistance 
was quite long in the initial reports, but others have now 
observed that the period for attainment of resistance can 
be considerably shortened. Despite the solid resistance 
of these animals to infection, the nature of their immunity 
has not been determined. Indeed, it is possible that their 
resistance is not immunological t all, although that seems 
rather unlikely. 
These results reveal a theme that characterizes most 
situations in which infections with live SIVs and HIVs in- 
duce protective immunity. Such protected individuals con- 
tinue to harbor the "immunizing" virus. It seems paradoxi- 
cal that a response powerful enough to prevent infection 
by a virulent virus cannot fully rid the host of an infection 
with an attenuated virus. There are precedents for this in 
the study of immune responses to tumors in which the 
concept of concomitant immunity, the ability to reject a 
transplant of a tumor identical to one borne by an animal, 
was developed. In both instances, principles of local immu- 
nity and of elimination of the pathogen in some particularly 
vulnerable state need consideration. Thus, it is possible 
that the effective immune status that nonetheless fails to 
purge existing virus may be quite effective in limiting the 
transmission of virus in the pool of cells in which virus 
normally turns over quite rapidly (Ho et al., 1995; Wei et 
al., 1995). By contrast, in cellular reservoirs in which the 
virus is retained for long periods of time (possibly macro- 
phages), immunity may have very limited effectiveness. 
Other considerations may have to deal with the likelihood 
that establishing an infection may prove to be a consider- 
ably more difficult challenge for the virus than maintaining 
one. For example, local immunity at mucosal surfaces may 
prevent access of HIV to critical sites. 
However, an important issue that needs further explora- 
tion is the possibility, indeed the likelihood, that solid im- 
munity will only be observed as long as the attenuated 
virus is retained. There is considerable controversy in the 
immunological literature as to whether the retention of im- 
munological memory requires the persistence of antigen 
(Grossman and Paul, 1992). Closely related is a contro- 
versy over how long a memory cell is retained without 
proliferation. Is memory a property of a long-lived nonpro- 
liferating cell, or is continued antigenic stimulation re- 
quired to retain the state of immunological memory? If the 
latter is the case, viruses that are so attenuated that they 
cannot replicate sufficiently to sustain their presence in 
the host will probably fail to induce a state of protective 
immunity. Indeed, I will return to this point later in consider- 
ing the potential pathogenicity of attenuated viruses. 
Chimpanzees may also display an apparently compara- 
ble state of immunity. Chimpanzees are resistant o the 
induction of disease by HIV-1; accordingly, those infected 
with the LAV/IIIB (IIIB) strain of HIV-1 fail to develop any 
evidence of disease. Recently, Martin and his colleagues 
have isolated a strain of HIV-1, DH12, that appears to elicit 
greater viral burdens in chimpanzees than other strains 
of HIV (Shibata et al., 1995). Chimpanzees inoculated with 
DH12 can display lymphadenopathy. Chimpanzees pre- 
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viously infected with IIIB are resistant to infection even 
with very large amounts of DH12. Just as was the case 
with the macaques infected with attenuated SlV, these 
chimpanzees, although resistant o DH 12, continue to ex- 
press IIIB sequences. Thus, an inability to purge an ex- 
isting virus coexists with a state of solid immunity capable 
of preventing (or perhaps eliminating) a new infection, 
even with a more virulent virus. However, not all infections 
with one HIV prevent superinfection with another (Fultz 
et al., 1994); what the determinants are that distinguish 
the two sets of observations has not yet been clarified. 
These results are consistent with the general experience 
that virus isolated from most HIV-infected adults appears 
to represent the quasispecies that could have emerged 
from a single infecting virus (Saag et al., 1988). Since 
many HIV ÷ individuals have been exposed to virus from 
more than one infected individual, the presence of but a 
single type of H IV suggests that, once infected, resistance 
to a second infection occurs. Indeed, this would be consis- 
tent with the concept that even highly virulent HIV may 
elicit an immune response that prevents infection with an- 
other HIV, but that fails to purge the existing virus. One 
must interpret his indirect argument with some care; an 
alternative xplanation would be that one virus is selected 
from many because of its superior "fitness" and comes to 
dominate a host despite the possibility that several viruses 
may have infected the individual, either simultaneously or 
sequentially. Indeed, there is persuasive evidence that 
viruses exist that must have arisen by recombination from 
"parents" of two different clades (Robertson et al., 1995). 
Such recombination would require a coinfection (simulta- 
neous or sequential) of a single host with distinct viruses. 
Unfortunately, we know very little about the nature of 
the protective immunity induced by an infecting virus. Cell 
transfer experiments, the classical tool for evaluating the 
cellular elements underlying an immune response, are not 
generally feasible in macaques, except in the unusual situ- 
ation in which twins exist. Indeed, the full value of the SIV/ 
macaque model as a tool for understanding the nature of 
the pathogenesis of lentivirus infection and the nature of 
protective immunity will not be realized unless techniques 
are developed for the routine twinning of macaques so 
that genetically identical individuals exist between whom 
cells can be transferred without rejection. Serum transfers 
have been carried out, revealing that sera from monkeys 
infected with virulent SIV can protect naive cynomolgus 
monkeys against infection (Putkonen et al., 1991). This 
result indicates the potential importance of antibody in 
protection against infection. Whether sera from macaques 
infected with nef-deficient SIV has similar protective ca- 
pacity is not yet known. 
Do Humans Display Immunity Induced 
by Attenuated HIVs? 
Attenuated HIVs have been recovered from humans in 
whom infection has had a very benign course. Desrosiers 
and his colleagues (Kirchhoff et al., 1995) described one 
such individual with no sign of disease and a normal CD4 
cell count more than 10 years after infection. Molecular 
analysis of the patient's HIV-1 over this extended period 
revealed a deletion in the nef gene that was sustained 
and, indeed, extended. Another interesting example is 
provided by a set of individuals in Australia each infected 
by blood products from a single donor (Learmont et al., 
1992). All of those infected in this way displayed a benign 
course with the exception of one who was being treated 
with glucocorticoids for systemic lupus erythematosus. 
Can attenuated viruses yield a state of concomitant im- 
munity in humans? The examples cited do not offer formal 
proof that the attenuated viruses induce protective immu- 
nity in humans. That would require that subjects infected 
with an attenuated virus were resistant o a challenge with 
a fully virulent virus that would infect most nonprotected 
individuals. However, there are some provocative obser- 
vations that suggest that HIV-2 may induce such immunity, 
protecting against infection with HIV-1 (or controlling HIV-1 
infection). HIV-2 is a less virulent lentivirus, related to HIV-1, 
that is being transmitted in some areas in Africa in which 
HIV-1 is also found. Among a set of prostitutes in the Gam- 
bia, a group have been identified that have appeared to 
escape HIV-1 infection despite several years of potential 
exposure to HIV-l-infected sex partners (Rowland-Jones 
et al., 1995). Many of these women have CTLs that recog- 
nize peptides shared by HIV-1 and HIV-2, suggesting that 
an inapparent infection with HIV-2 may have elicited an 
immune response capable of cross-protection. 
This indirect experiment receives support from a recent 
epidemiological study conducted on another group of 
prostitutes in Dakar, Senegal, from 1985-1994 (Travers 
et al., 1995). They were segregated into H IV-2 ÷ and HIV-2- 
groups, and the risk of subsequent infection with HIV-1 
was determined for the two groups. Over an extended 
period of observation, the relative risk of infection with 
HIV-1 of the H IV-2 ÷ women was one third that of the H IV-2- 
women. The possibility that the HIV-2 + women might have 
altered their behavior so as to be at lower risk of subse- 
quent HIV-1 infection was considered. It was argued that 
rates of infection with other sexually transmitted microor- 
ganisms would provide an observational test of whether 
such behavior modification had occurred. The result was 
that the HIV-2 ÷ women had a rate of sexually transmitted 
diseases at least as great as the HIV-2- women. Thus, 
the most likely explanation is that infection with HIV-2 pro- 
vided a state of immunity that protected some of these 
women against infection with HIV-I. 
Could Attenuated HIVs Form the Basis of Vaccines? 
In view of the relatively disappointing outcomes that have 
been obtained thus far with other vaccine candidates, the 
results of these experiments create inevitable nthusiasm 
for the possible use of attenuated live HIVs as protective 
vaccines. Unfortunately, the barriers to such use are quite 
daunting. It would have to be demonstrated that the risk 
of the virus reverting to its virulent state would be very low 
and that the deletions used to attenuate the virus actually 
rendered the virus nonpathogenic. The latter is not a trivial 
point, since we do not yet understand the determinants 
of pathogenicity. The major determinant of pathogenicity 
of H IVs and SIV may be their capacity to replicate; alterna- 
tively, specific gene products may be required for induction 
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of the disease even in the face of replication competence 
(Coffin, 1995). Thus far, the test in preparing attenuated 
viruses has been diminished replication competence of 
the virus. However, if that criterion were to prove inade- 
quate, it is possible that recovery of virulence might occur 
under unanticipated circumstances. 
Indeed, a rather dramatic example of unanticipated viru- 
lence of an attenuated virus has recently been reported. 
Ruprecht and her colleagues (Baba et al., 1995) showed 
that an SIV in which there was a deletion in the nefgene, 
as well as in vpr, although strikingly attenuated in adult 
macaques, was capable of initiating infection and disease 
when fed in large amounts to neonates within 1 hr of birth. 
While the reasons for the susceptibility of the neonates 
was not established, it seems likely that the immaturity of 
their immune systems and their relative immunoincompe- 
tence may explain it. indeed, it is well known that many 
murine oncogenic retroviruses must be inoculated into ne- 
onates if tumors are to be induced; adults generally make 
a vigorous immune response and eliminate the virus 
(Weiss et al., 1984). 
Would the risk of transmission from a woman vaccinated 
with an attenuated virus to her infant rule out the use of 
such viruses as vaccines? One could easily imagine that 
this problem could be mitigated by avoiding the vaccina- 
tion of pregnant women. While it is anticipated that the 
attenuated virus would persist in the vaccinee, once the 
initial infection has been controlled viral titers should be 
exceedingly low, as they are in adult macaques that have 
been infected with nef-defective SIV. Thus, the chance of 
transmission, which appears to be linked to viral burden, 
is likely to be very low. 
However, this does not mean that the implications of 
this experiment do not constitute a serious impediment o 
the introduction of an attenuated live HIV vaccine. If the 
proper explanation for the susceptibility of neonates is 
their relatively immunoincompetency, there would have 
to be a serious concern about the potential susceptibility 
of immunosuppressed adults or adults that are immuno- 
compromised for other reasons. Furthermore, since acti- 
vated CD4 cells appear to be particularly susceptible to 
HIV infection, it is conceivable that the balance between 
HIV control and growth might be tipped in the course of 
an intercurrent infection, in which vigorous T cell activation 
may be occurring. 
The bottom line of this consideration of the potential 
usefulness of attenuated live HIV vaccines in humans is 
that extensive safety testing would certainly be required 
before such use could be considered in any large popula- 
tion. Safety testing would inevitably carry a substantial 
risk and would have to meet very high ethical standards. 
Possibly, individuals who were members of groups at very 
high risk of infection and in whom behavior modification 
strategies had failed might be potential participants in 
such trials. Under any set of circumstances, such trials 
would have to start with small numbers and would eventu- 
ally require quite long observational periods, not only be- 
cause of the risk of the recovered virulence of the virus 
after long periods of time, possibly late in life with the 
immunodeficiency of old age, but also because insertional 
mutagenesis might increase the likelihood of neoplasms. 
Thus, attenuated viruses have provided the most robust 
protection against infection with virulent virus. Nonethe- 
less, it has not been unequivocally established that the 
protection is immunological. Assuming that it is, the im- 
mune mechanisms that account for it are still not known. 
Establishing efficacy will be sufficiently daunting that only 
in settings with a very high transmission rate is it likely 
that such a vaccine could be used, at least initially. On 
the other hand, the need to establish the immunological 
mechanisms underlying this protection is paramount. 
Clearly, we now have an example in macaques and possi- 
bly in HiV-2-infected humans of a state of protective immu- 
nity. In that respect, we are now closer than before to 
developing an understanding of the nature of immune pro- 
tection against HIV. Understanding the basis of protection 
would obviously provide a standard to help in guiding the 
development of other vaccine candidates. 
Prospects for Immunological Control of HIV 
Although a complete review of vaccine strategies that 
could be used for HIV is beyond the scope of this review, 
certain key issues certainly bear discussion. The issue of 
whether subunit vaccines could be effective has not been 
resolved, but the first generation attempts with soluble 
gp120 preparations used either with alum or with MF59 
(an oil in water adjuvant) have proved disappointing. That 
is not to imply that such vaccines fail to evoke an immune 
response or that, under certain very specified conditions, 
they do not elicit protection. Indeed, subjects immunized 
with several courses of gp120 do develop antibodies reac- 
tive with the immunizing viral strain, although titers tend 
to decline rapidly after each boost. The titers against other 
strains tend to be substantially lower than those against 
the immunizing strain (Schwartz et al., 1993). There is 
also considerable controversy regarding the neutralizing 
capacity of the elicited antibody. When tested against tis- 
sue culture-adapted strains of HiV and in assays measur- 
ing infection of established cell lines, sera from immunized 
subjects often display a substantial neutralizing titer. How- 
ever, when clinical isolates are used as a source of virus 
and PBMCs as the target cells, little or no neutralizing 
capacity of the sera are observed. Whether this reflects 
a physiologically important difference and which of the 
two assays is more relevant to in vivo infection are not 
clear. 
It is true that a series of chimpanzees that had received 
several courses of prior immunization with a gp120 prepa- 
ration were protected against a challenge with HIV admin- 
istered shortly after their last immunization (Berman et 
al., 1990; Duliege, 1994). This could reflect a stronger 
neutralizing capacity than that suggested by in vitro 
assays. Alternatively, and rather more likely, it could be 
explained by the fact that chimpanzees do not support a 
high degree of viral replication and, thus, should provide 
a particularly easy setting in which to eliminate virus. 
In any case, a decision not to proceed to efficacy testing 
in the United States with this preparation has been made, 
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although a World Health Organization expert committee 
has recommended trials with gp120 preparations in areas 
with high transmission rates, such as Thailand. Currently, 
much effort is being expended on canarypox vectors into 
which HIV genes, such as gag, pol, and env, have been 
cloned. Primary immunization with such recombinants to- 
gether with boosts with soluble gp120 has been suggested 
based on experience in macaques. Unfortunately, initial 
studies with canarypox recombinants indicate that they 
may be of less than optimal immunogenicity (Plotkin, 
1994), possibly because they fail to replicate in human 
cells (Cox et al., 1993). However, recombinants based on 
other pox viruses or possibly other viral vectors that sup- 
port substantially greater replication may prove more ef- 
fective as immunogens. Other approaches, such as the 
use of naked DNA specifying HIV antigens and eliciting 
the expression of cellular costimulants (such as B7), are 
also receiving considerable attention. Unfortunately, with- 
out further understanding of the means through which at- 
tenuated vaccines elicit protection, we will be forced to 
make certain major assumptions as to the type of immunity 
that is likely to be protective and to design immunization 
protocols that appear most likely to elicit this form of im- 
munity. 
An obvious area to examine is whether influencing the 
quality of an immune response might enhance the protec- 
tive value of those responses. Two important subjects are 
the control of the balance of cytokines that are produced 
and the enhancement of the degree of expression of immu- 
nity at mucosal surfaces. 
Favoring the induction of HIV-specific IFNy-producing 
T cells and CTLs over T cells that mainly produce interleu- 
kin-4 (IL-4) and related cytokines, including IL-5 and IL-10, 
has been strongly suggested not only as an immunization 
strategy but also as a means to make ongoing immune 
responses in infected individuals more effective. Studies 
in experimental animals suggest that the regulation of the 
quality of immune responses, while it may be influenced 
by antigen dose, as Shearer has already indicated, is con- 
trolled principally by the cytokines available at the time of 
priming (Paul and Seder, 1994). In particular, IL-4 appears 
to inhibit priming for IFNy production by T cells and IL-12 
appears to strikingly enhance priming for IFNy production. 
Whether the use of cytokines in vaccine protocols would 
be effective and, if effective, feasible remains to be deter- 
mined. 
The enhancement of mucosal immunity, particularly at 
the sites where transmission normally occurs, has been 
emphasized as an important goal in preventing transmis- 
sion. Strategies that may elicit such enhanced mucosal 
responses include immunization at mucosal sites, the use 
of vectors, such as poliovirus (Andino et al., 1994), that 
may favor induction of mucosal immunity (Cox et al., 
1993), and the use of cholera toxin B subunit as an adju- 
vant, which may aid in the development of mucosal immu- 
nity (Vajdy and Lycke, 1992). 
Conclusion 
Experience thus far strongly indicates that solid immunity 
to HIV and SIV can be generated most effectively by living 
viruses. The epidemiological evidence that HIV-2 infection 
may offer protection against infection with HIV-1 implies 
that a substantial degree of cross-protection is possible, 
indicating that HIV mutational variability may not be as 
serious a problem as we had feared. For the moment, it 
seems unlikely that live attenuated viruses will come into 
use as vaccines in the developed world; whether particu- 
larly high risk areas of the developing world may constitute 
sites where such vaccines could be used ethically will re- 
main to be seen. Thus, while it is essential that experi- 
ments go forward to clarify the nature of protection to SlV, 
in the short run the main goal of such experiments will be 
to understand the mechanism of immunity in the hope 
that it can be duplicated by other vaccines. In view of the 
world-wide nature of the AIDS epidemic and the fact that 
most infected individuals live in parts of the developing 
world in which drug therapy may prove to be too expensive 
for routine use, the importance of effective vaccines can- 
not be overstated. Moreover, prevention of transmission 
opens the possibility for the control of the epidemic, which 
is unlikely to be achieved by any therapeutic strategy. 
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